Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD B POWELL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1023103702
CMS profile
819362
Location
NEW PORT RICHEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$39.93

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $39.93 2

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Vanda Pharmaceuticals Inc. $28.82 1
Amarin Pharma Inc. $11.11 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD B POWELL

NPI 1023103702 · CMS profile ID 819362

Allopathic & Osteopathic Physicians / Internal Medicine

NEW PORT RICHEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023103702?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023103702?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023103702?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1023103702?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $39.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vanda Pharmaceuticals Inc. $28.8206/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735141111 CMS
Amarin Pharma Inc. $11.1101/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740008645 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,998.99 5
PY2020 $39.93 2
PY2023 $3,086.41 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $123,379.85 19
PY2024 Principal investigator $519,613.32 181
PY2023 Principal investigator $3,705,517.67 2,390
PY2022 Principal investigator $2,801,811.98 590
PY2021 Principal investigator $422,228.81 39
PY2020 Principal investigator $83,061.46 21
PY2019 Principal investigator $408,254.19 140

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

2,390 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $101,976.05 12/15/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040222517
Principal investigator 1 ModernaTX, Inc. $69,991.25 12/15/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040222629
Principal investigator 1 Seqirus USA Inc $587.00 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347483
Principal investigator 1 Seqirus USA Inc $587.00 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347497
Principal investigator 1 Seqirus USA Inc $587.00 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347513
Principal investigator 1 Seqirus USA Inc $587.00 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347527
Principal investigator 1 Seqirus USA Inc $587.00 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347541
Principal investigator 1 Seqirus USA Inc $587.00 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347555
Principal investigator 1 Seqirus USA Inc $587.00 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347571
Principal investigator 1 Seqirus USA Inc $587.00 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347585
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347599
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347615
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347629
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347645
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347659
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347675
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347691
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347705
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347721
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347735
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347749
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347765
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347779
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347795
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347811
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347825
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347841
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347855
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347869
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347883
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347899
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347915
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347929
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347943
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347959
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347973
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021347989
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021348003
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021348021
Principal investigator 1 Seqirus USA Inc $2,692.14 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021348035
Principal investigator 1 Seqirus USA Inc $2,692.15 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021348049
Principal investigator 1 Seqirus USA Inc $2,692.15 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021348063
Principal investigator 1 Seqirus USA Inc $2,692.15 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021348077
Principal investigator 1 Seqirus USA Inc $2,692.15 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021348093
Principal investigator 1 Seqirus USA Inc $2,692.15 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021348109
Principal investigator 1 Seqirus USA Inc $2,692.15 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021348123
Principal investigator 1 Seqirus USA Inc $2,692.15 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021348137
Principal investigator 1 Seqirus USA Inc $2,692.15 12/11/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021348151
Principal investigator 1 ModernaTX, Inc. $225.86 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040010711
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011619
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011625
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011631
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011637
Principal investigator 1 ModernaTX, Inc. $320.56 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011643
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011649
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011653
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011661
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011665
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011671
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012775
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012781
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012787
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012793
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012799
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012805
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012811
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012817
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040012823
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013489
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013497
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013505
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013513
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013521
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013529
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013537
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013545
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013553
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013561
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013569
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013577
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040013583
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040014581
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040014587
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040014592
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040014597
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040014603
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040014609
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040014615
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040014621
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015755
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015761
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015767
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015773
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015779
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015785
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015791
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015797
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015801
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015809
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015813
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015819
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015825
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015831
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015839
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015845
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015851
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015857
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015863
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015869
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015875
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015881
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015887
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015893
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040015899
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017283
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017289
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017295
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017301
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017309
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017315
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017321
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017327
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017331
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017339
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040017345
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018927
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018933
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018939
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018945
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018951
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018957
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018963
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018969
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018975
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018983
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018989
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040018995
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019001
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019007
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019013
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019019
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019025
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019031
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019037
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019043
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019049
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019055
Principal investigator 1 ModernaTX, Inc. $271.55 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019059
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019063
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019069
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019075
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019081
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019087
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019093
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040019099
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021123
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021133
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021145
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021153
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021163
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021173
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021185
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021195
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021205
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021215
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021225
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021235
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021245
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040021255
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024133
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024143
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024153
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024163
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024173
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024183
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024193
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024203
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024213
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024223
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024235
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024243
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024253
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024267
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024277
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024287
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024297
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024307
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024317
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040024327
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040027029
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040027039
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040027047
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040027057
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028725
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028735
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028743
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028755
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028765
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028774
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028785
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028795
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028805
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028813
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028821
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028831
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028841
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028854
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028861
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028873
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028881
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028891
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028901
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028911
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028921
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028931
Principal investigator 1 ModernaTX, Inc. $225.86 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040028941
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029885
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029895
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029903
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029915
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040029925
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040031651
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040031661
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040031671
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040031681
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040031693
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040031701
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040031715
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033473
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033483
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033493
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033501
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033511
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033521
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033531
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033539
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033549
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033559
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033569
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033577
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033589
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040033598
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034599
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034609
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034619
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034629
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034639
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034649
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034659
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034669
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034679
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034688
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034697
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034709
Principal investigator 1 ModernaTX, Inc. $225.86 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034719
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034729
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034741
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040034751
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036499
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036509
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036519
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036529
Principal investigator 1 ModernaTX, Inc. $320.56 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036540
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036549
Principal investigator 1 ModernaTX, Inc. $320.56 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036561
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036569
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040036581
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039215
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039225
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039235
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039245
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039255
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039265
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039275
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039285
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039295
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039307
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039317
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039327
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039337
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039347
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039357
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039367
Principal investigator 1 ModernaTX, Inc. $271.55 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039379
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039389
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039401
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039411
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039419
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039429
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039439
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039449
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040039461
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040042105
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040042115
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040042125
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040042135
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040042143
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040042153
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040042165
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040042175
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044077
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044087
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044097
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044109
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044119
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044129
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044137
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044149
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044161
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044170
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044179
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044189
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044200
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044209
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044219
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044229
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044239
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044249
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044259
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044271
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044281
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044291
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044301
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044315
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040044325
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040046721
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040046733
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040046743
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040046753
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040046763
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040046773
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040046783
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040046793
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040046803
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040046813
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040046823
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048899
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048909
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048919
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048929
Principal investigator 1 ModernaTX, Inc. $271.55 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048939
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048951
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048961
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048971
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048981
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040048991
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049001
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049015
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049025
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049035
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049045
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049055
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049065
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049075
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049085
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049095
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049105
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049117
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049127
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049137
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049147
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040049157
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040051517
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040051527
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040051539
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040051549
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054173
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054181
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054193
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054203
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054217
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054229
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054239
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054251
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054261
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054271
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054281
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054291
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054303
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054313
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054323
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054331
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054341
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054353
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054361
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054371
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054381
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040054391
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040055301
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040055311
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040055323
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040055333
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040055343
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040055353
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040055363
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040055371
Principal investigator 1 ModernaTX, Inc. $320.56 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040057447
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040057457
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040057465
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040057473
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059163
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059171
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059179
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059187
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059195
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059203
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059211
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059219
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059227
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059235
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059243
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059251
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059259
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059267
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059275
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059283
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059291
Principal investigator 1 ModernaTX, Inc. $225.86 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059299
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059307
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059315
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059323
Principal investigator 1 ModernaTX, Inc. $225.86 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059331
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059339
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059347
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059357
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059365
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040059373
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040061849
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040061861
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040061871
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040061881
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040061893
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063827
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063839
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063849
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063859
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063869
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063881
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063889
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063899
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063909
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063919
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063929
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063939
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063949
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063959
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063969
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063979
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063989
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040063999
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040064009
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040064019
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040066809
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040066819
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040066829
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040066839
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040066849
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040066861
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040066871
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040066881
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040066891
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040066899
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068909
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068921
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068931
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068939
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068949
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068959
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068969
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068979
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068989
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040068999
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069009
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069019
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069029
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069039
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069049
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069059
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069069
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069079
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069089
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069099
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069109
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069119
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069127
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069141
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069153
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069163
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069173
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069183
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069193
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069203
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069213
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040069223
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040071479
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040071491
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040071499
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040071507
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040071521
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040071529
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040071539
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074511
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074521
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074531
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074541
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074551
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074561
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074571
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074581
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074591
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074601
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074611
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074625
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074635
Principal investigator 1 ModernaTX, Inc. $225.86 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074645
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074655
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074665
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074675
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074685
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074695
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040074705
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076325
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076335
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076345
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076355
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076365
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076375
Principal investigator 1 ModernaTX, Inc. $320.56 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076385
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076395
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076403
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076411
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040076421
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078275
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078283
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078293
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078303
Principal investigator 1 ModernaTX, Inc. $225.86 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040078313
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079363
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079371
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079381
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079391
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079401
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079413
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079423
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079433
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079443
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079453
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079463
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079473
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079483
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079493
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079499
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079511
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079521
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079529
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040079541
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081197
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081207
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081217
Principal investigator 1 ModernaTX, Inc. $320.56 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081227
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081237
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081247
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081257
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081267
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040081277
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083317
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083325
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083335
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083345
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083355
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083363
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083373
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083385
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083395
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083405
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083417
Principal investigator 1 ModernaTX, Inc. $271.55 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083427
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083437
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083447
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083457
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083467
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083477
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083487
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083497
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083507
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083517
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083527
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083537
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083547
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040083557
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040084503
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040084517
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040084527
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040084537
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040084547
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040084555
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086025
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086035
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086045
Principal investigator 1 ModernaTX, Inc. $320.56 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086055
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086065
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086075
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086085
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086093
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086103
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086117
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086127
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086137
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040086145
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040087063
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040087073
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040087083
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088725
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088735
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088745
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088755
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088765
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088775
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088785
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088795
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088805
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088815
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088825
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088835
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088845
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088855
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088865
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088875
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088885
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088897
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088907
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088917
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088927
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088937
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040088947
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040091765
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040091773
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040091783
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040091793
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040091805
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093733
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093743
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093755
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093765
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093775
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093785
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093795
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093805
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093815
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093825
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093835
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093845
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093855
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093865
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093875
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093887
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093897
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093907
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093917
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093927
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040093939
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096669
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096679
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096689
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096699
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096711
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096721
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096733
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040096743
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098675
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098685
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098697
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098705
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098717
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098727
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098737
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098747
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098755
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098765
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098775
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098785
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098795
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098803
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098813
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098823
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098835
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098847
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098855
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098867
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098877
Principal investigator 1 ModernaTX, Inc. $271.55 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098887
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098895
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098905
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098917
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098927
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098935
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098947
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098957
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098967
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098973
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040098985
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040100849
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040101839
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040101849
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040101859
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040101869
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040101879
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040101891
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040101901
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040101911
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040101921
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040101931
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104091
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104101
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104111
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104121
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104133
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104143
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104153
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104163
Principal investigator 1 ModernaTX, Inc. $271.55 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104173
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104185
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104195
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104205
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104215
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104228
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104241
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104251
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104263
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104275
Principal investigator 1 ModernaTX, Inc. $271.55 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104287
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104299
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104311
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104324
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104339
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040104351
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040106919
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040106929
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040106941
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040106955
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040106969
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040106981
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040106994
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040107007
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040107019
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040107031
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040107043
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109295
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109307
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109321
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109333
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109345
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109357
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040109371
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110521
Principal investigator 1 ModernaTX, Inc. $225.86 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110533
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110545
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110557
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110569
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110581
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110593
Principal investigator 1 ModernaTX, Inc. $225.86 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110605
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110617
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110631
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110645
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110657
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110669
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110681
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110695
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110707
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110719
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110731
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110743
Principal investigator 1 ModernaTX, Inc. $271.55 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110755
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110767
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110779
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110791
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110805
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110817
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040110831
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040113663
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040113675
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040113687
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040113699
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040113711
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040113727
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040113739
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115871
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115883
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115895
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115907
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115919
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115931
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115943
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115955
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115967
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115979
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040115993
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116005
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116017
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116029
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116041
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116053
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116065
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116079
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116091
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116103
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116121
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116133
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116145
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116157
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116169
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116181
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040116193
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040117343
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040117357
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040117369
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040117381
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040117391
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040117405
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040117417
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040117427
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040119385
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040119397
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040119409
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040119421
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040119433
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121749
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121761
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121773
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121785
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121797
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121809
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121821
Principal investigator 1 ModernaTX, Inc. $271.55 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121835
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121845
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121857
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121871
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121883
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121895
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040121907
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040123189
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040123201
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040123213
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040123225
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040123237
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040123249
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040123261
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040123275
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040123287
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040123301
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040125087
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040125101
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040125113
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040125127
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040126307
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040126319
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040126331
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040126345
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040126361
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040126373
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040126385
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040126395
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128189
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128201
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128213
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128225
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128239
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128251
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128263
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128275
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128287
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128299
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128311
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128325
Principal investigator 1 ModernaTX, Inc. $225.86 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128337
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128349
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128361
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128373
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128389
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128403
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128415
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128427
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128439
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128451
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040128465
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040129515
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040129527
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040129539
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040129551
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040129563
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040129577
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040129589
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040129601
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040131851
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040131863
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040131875
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134847
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134859
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134871
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134885
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134897
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134909
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134923
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134935
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134947
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134959
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134971
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134983
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040134999
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135013
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135027
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135041
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135052
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135063
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135077
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135089
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135101
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135113
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135127
Principal investigator 1 ModernaTX, Inc. $271.55 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135139
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135151
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135163
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135175
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135187
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135199
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135215
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135229
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135241
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135253
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135265
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135277
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135291
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135303
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040135315
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040136439
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040139241
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040139255
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040139267
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040139279
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040139291
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040139303
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040139315
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141661
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141673
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141685
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141695
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141707
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141719
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141731
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141745
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141759
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141771
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141783
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141797
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141809
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141821
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141833
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141845
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141857
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141869
Principal investigator 1 ModernaTX, Inc. $225.86 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141883
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141895
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141907
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141919
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040141931
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040144099
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040144111
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040145313
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040145325
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040145338
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040145351
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147819
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147831
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147843
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147855
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147867
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147879
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147891
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147905
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147917
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147929
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147941
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147953
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147965
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147979
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040147989
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040148001
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040148013
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040148025
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040151255
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040151267
Principal investigator 1 ModernaTX, Inc. $320.56 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040151279
Principal investigator 1 ModernaTX, Inc. $320.56 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040151291
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040151303
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040151315
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040151327
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040151339
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153521
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153533
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153545
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153556
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040153567
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154801
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154813
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154825
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154835
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154847
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154859
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154871
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154885
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154897
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154907
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154919
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154931
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154945
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154955
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154967
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154983
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040154995
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040155007
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040155019
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040155031
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040155041
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040155053
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040155067
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040157391
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040157403
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040157417
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040157429
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040157443
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040157456
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040157469
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040157479
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040157491
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040157503
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159761
Principal investigator 1 ModernaTX, Inc. $271.55 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159775
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159787
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159801
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159813
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159825
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159837
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159849
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159861
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159873
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159885
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159897
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159909
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159921
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040159933
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040161249
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040161261
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040161273
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040161285
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040161297
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040161309
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040161324
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040163301
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040163313
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040163325
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040163337
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040163349
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040163361
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040163373
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040165591
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166805
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166815
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166829
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166837
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166850
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166861
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166875
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166888
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166901
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166913
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166924
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166937
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166947
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166963
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166973
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166985
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040166999
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040167011
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040167025
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040167037
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040167049
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040167061
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040167075
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169147
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169159
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169171
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169185
Principal investigator 1 ModernaTX, Inc. $320.56 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169197
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169209
Principal investigator 1 ModernaTX, Inc. $320.56 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169223
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169234
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169245
Principal investigator 1 ModernaTX, Inc. $300.34 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169259
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169273
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169285
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169297
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040169309
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171585
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171597
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171609
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171621
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171633
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171649
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171663
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171675
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171687
Principal investigator 1 ModernaTX, Inc. $225.86 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171699
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171713
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171723
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171738
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171751
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171763
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171775
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171787
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171799
Principal investigator 1 ModernaTX, Inc. $271.55 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171813
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171825
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040171839
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040173057
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040173069
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040173081
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040173091
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040173103
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040174947
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040174961
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040174975
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040176307
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040176321
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040176335
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040176351
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040176367
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040176381
Principal investigator 1 ModernaTX, Inc. $320.56 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040176395
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040176413
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177799
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177813
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177827
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177841
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177857
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177871
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177885
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177899
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177911
Principal investigator 1 ModernaTX, Inc. $404.93 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177927
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177939
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177955
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177967
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177984
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040177999
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178015
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178029
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178043
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178057
Principal investigator 1 ModernaTX, Inc. $130.28 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178079
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178093
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178105
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178121
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178135
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178149
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178163
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178173
Principal investigator 1 ModernaTX, Inc. $59.80 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178189
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178205
Principal investigator 1 ModernaTX, Inc. $73.30 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178225
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178243
Principal investigator 1 ModernaTX, Inc. $80.73 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178257
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178271
Principal investigator 1 ModernaTX, Inc. $1.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040178285
Principal investigator 1 ModernaTX, Inc. $54,787.20 11/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040220413
Principal investigator 1 Roche Diagnostics Operations, Inc. $8,415.00 11/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051510645
Principal investigator 1 Roche Diagnostics Operations, Inc. $3,150.00 11/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051511439
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,789.20 11/20/2023 Non-covered Recipient Entity
Velocity Clinical Research
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1022137893
Principal investigator 1 ModernaTX, Inc. $101.25 11/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039973127
Principal investigator 1 ModernaTX, Inc. $101.25 11/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039973133
Principal investigator 1 ModernaTX, Inc. $10,400.00 11/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039973139
Principal investigator 1 ModernaTX, Inc. $101.25 11/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039973145
Principal investigator 1 ModernaTX, Inc. $101.25 11/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039973149
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $2,979.21 11/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH CINCINNATI
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy No dispute reported 06/30/2026 1006165959
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,500.00 11/02/2023 Non-covered Recipient Entity
Velocity Clinical Research Durham
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1022139465
Principal investigator 1 Boehringer Ingelheim International GmbH $1,380.40 11/01/2023 Non-covered Recipient Entity
Velocity Clinical Research
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1007646529
Principal investigator 1 Roche Diagnostics Operations, Inc. $3,018.72 10/31/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051510955
Principal investigator 1 Roche Diagnostics Operations, Inc. $3,270.80 10/31/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051511309
Principal investigator 1 Roche Diagnostics Operations, Inc. $1,040.00 10/31/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051511327
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039961263
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039961269
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039961275
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962081
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962087
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962091
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962187
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962193
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962199
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962203
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962209
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962445
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962451
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962457
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962463
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962469
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962801
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962807
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039962813
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963085
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963371
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963375
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963773
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963779
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039963785
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964195
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964201
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964207
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964213
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964219
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964661
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964667
Principal investigator 1 ModernaTX, Inc. $1,172.47 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039964939
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965619
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965625
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965631
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965637
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965643
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965649
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965987
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965993
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039965999
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966005
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966011
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966017
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966197
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966515
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966521
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966527
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966535
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966541
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966549
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039966919
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967307
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967313
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967489
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967495
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967499
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967507
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967923
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039967931
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968259
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968265
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968271
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968277
Principal investigator 1 ModernaTX, Inc. $1,172.47 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968283
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968505
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968515
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968521
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968527
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968535
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968687
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968693
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968699
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968705
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968711
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039968717
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969349
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969355
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969359
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969637
Principal investigator 1 ModernaTX, Inc. $1,172.47 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969645
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969651
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969657
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969663
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969669
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969673
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969819
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039969825
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970289
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970297
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970341
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970347
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970717
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970723
Principal investigator 1 ModernaTX, Inc. $1,172.47 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970771
Principal investigator 1 ModernaTX, Inc. $3,644.40 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970777
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970783
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970789
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039970795
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971343
Principal investigator 1 ModernaTX, Inc. $1,172.47 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971685
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971691
Principal investigator 1 ModernaTX, Inc. $1,172.47 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971697
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971901
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971907
Principal investigator 1 ModernaTX, Inc. $1,172.47 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971913
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039971919
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039972357
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039972363
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039972369
Principal investigator 1 ModernaTX, Inc. $659.75 10/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039972377
Principal investigator 1 ModernaTX, Inc. $97,996.70 10/27/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040218611
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039917655
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039917669
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039919123
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039923467
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039923479
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039925511
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039928799
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039928809
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039930705
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039930715
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039933327
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039940508
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039942107
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039944885
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039948361
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039948367
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039951033
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039953071
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039954143
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039954147
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039954153
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039954159
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039954769
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957439
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957445
Principal investigator 1 ModernaTX, Inc. $1,589.56 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039959559
Principal investigator 1 Seqirus USA Inc $9,000.00 10/23/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021338975
Principal investigator 1 Seqirus USA Inc $2,000.00 10/23/2023 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1021338989
Principal investigator 1 ModernaTX, Inc. $6,692.00 10/20/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040218549
Principal investigator 1 ModernaTX, Inc. $3,125.00 10/11/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040204617
Principal investigator 1 ModernaTX, Inc. $550.00 10/11/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040206793
Principal investigator 1 ModernaTX, Inc. $51,220.55 10/11/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040217853
Principal investigator 1 ModernaTX, Inc. $3,090.15 10/11/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040217959
Principal investigator 1 ModernaTX, Inc. $1,200.00 10/11/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040218329
Principal investigator 1 ModernaTX, Inc. $38,064.80 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040218071
Principal investigator 1 PFIZER INC. $24,767.00 09/27/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046164568
Principal investigator 1 ModernaTX, Inc. $3,148.54 09/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040217043
Principal investigator 1 ModernaTX, Inc. $72,884.80 09/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040217513
Principal investigator 1 PFIZER INC. $3,864.40 09/09/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880325
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039861129
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039861143
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039861355
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039861369
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039861383
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039861555
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039861801
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039861815
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039861829
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039861845
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039861859
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039862333
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039862347
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039862361
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039862375
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039862389
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039862405
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039862659
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039862855
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039862871
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039863209
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039863341
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039863355
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039863371
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039863553
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039863565
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039863847
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039863861
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039863875
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039863889
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864091
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864105
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864119
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864261
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864277
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864291
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864625
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864639
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864653
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864667
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864683
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864697
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039864711
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039865427
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039865447
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039865793
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039865811
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039865827
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039865845
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039865867
Principal investigator 1 ModernaTX, Inc. $1,589.56 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039865881
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039866269
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039866287
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039866305
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039866323
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039866341
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039866359
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039866377
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039866395
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039866415
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039866435
Principal investigator 1 ModernaTX, Inc. $1,855.52 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039866981
Principal investigator 1 ModernaTX, Inc. $112,466.80 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040216479
Principal investigator 1 Janssen Pharmaceuticals, Inc $6,395.00 09/01/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094915
Principal investigator 1 Roche Diagnostics Operations, Inc. $981.24 08/29/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051507799
Principal investigator 1 PFIZER INC. $3,053.46 08/24/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880341
Principal investigator 1 ModernaTX, Inc. $1,200.00 08/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039856771
Principal investigator 1 ModernaTX, Inc. $4,200.00 08/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039857659
Principal investigator 1 ModernaTX, Inc. $400.00 08/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039857673
Principal investigator 1 ModernaTX, Inc. $7,604.51 08/18/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040215779
Principal investigator 1 ModernaTX, Inc. $12,790.00 08/18/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040223543
Principal investigator 1 Janssen Pharmaceuticals, Inc $882.00 08/16/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094917
Principal investigator 1 ModernaTX, Inc. $98,926.40 08/16/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040215111
Principal investigator 1 Janssen Research & Development, LLC $6,860.00 08/11/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120315
Principal investigator 1 Janssen Research & Development, LLC $47,445.00 08/09/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120307
Principal investigator 1 ModernaTX, Inc. $2,500.00 08/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040203817
Principal investigator 1 ModernaTX, Inc. $22,610.00 08/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040203853
Principal investigator 1 ModernaTX, Inc. $500.00 08/01/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039854538
Principal investigator 1 ModernaTX, Inc. $1,278.00 07/28/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. No dispute reported 06/30/2026 1040214387
Principal investigator 1 ModernaTX, Inc. $116,515.60 07/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040213939
Principal investigator 1 Roche Diagnostics Operations, Inc. $8,651.16 07/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051509227
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,876.00 07/21/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094919
Principal investigator 2 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 07/18/2023 Non-covered Recipient Entity
Velocity Clinical Research
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000217229
Principal investigator 1 Janssen Research & Development, LLC $1,405.00 07/14/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120299
Principal investigator 1 PFIZER INC. $3,105.00 07/13/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880357
Principal investigator 1 Janssen Research & Development, LLC $102,912.00 07/10/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120291
Principal investigator 1 PFIZER INC. $7,860.00 07/06/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880371
Principal investigator 1 ModernaTX, Inc. $62,768.80 06/28/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040212555
Principal investigator 1 ABBVIE INC. $71.00 06/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998388151
Principal investigator 1 PFIZER INC. $3,452.68 06/27/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045880703
Principal investigator 1 Janssen Pharmaceuticals, Inc $890.00 06/26/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094767
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,339.00 06/21/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094765
Principal investigator 1 AstraZeneca UK Limited $6,647.00 06/15/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomised, Double-Blind, Placebo and Active Comparator-Controlled Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD5718 Given Orally Once Daily for Twelve Weeks in Adults with Moderate-to-Severe Uncontrolled Asthma No dispute reported 06/30/2026 991137583
Principal investigator 1 Roche Diagnostics Operations, Inc. $3,844.96 06/15/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051507817
Principal investigator 1 ModernaTX, Inc. $270.00 06/09/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786583
Principal investigator 1 ModernaTX, Inc. $105.30 06/09/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786589
Principal investigator 1 ModernaTX, Inc. $105.30 06/09/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786597
Principal investigator 1 ModernaTX, Inc. $121.50 06/08/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786603
Principal investigator 1 ModernaTX, Inc. $222.75 06/05/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786151
Principal investigator 1 ModernaTX, Inc. $121.50 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786231
Principal investigator 1 ModernaTX, Inc. $121.50 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786239
Principal investigator 1 ModernaTX, Inc. $121.50 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786247
Principal investigator 1 ModernaTX, Inc. $121.50 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786255
Principal investigator 1 ModernaTX, Inc. $121.50 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786263
Principal investigator 1 ModernaTX, Inc. $121.50 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786271
Principal investigator 1 ModernaTX, Inc. $121.50 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786277
Principal investigator 1 ModernaTX, Inc. $121.50 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786287
Principal investigator 1 ModernaTX, Inc. $121.50 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786293
Principal investigator 1 ModernaTX, Inc. $121.50 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786301
Principal investigator 1 ModernaTX, Inc. $121.50 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786309
Principal investigator 1 ModernaTX, Inc. $121.50 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786319
Principal investigator 1 ModernaTX, Inc. $75.00 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786327
Principal investigator 1 ModernaTX, Inc. $75.00 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786337
Principal investigator 1 ModernaTX, Inc. $75.00 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786345
Principal investigator 1 ModernaTX, Inc. $75.00 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786353
Principal investigator 1 ModernaTX, Inc. $75.00 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786361
Principal investigator 1 ModernaTX, Inc. $75.00 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786369
Principal investigator 1 ModernaTX, Inc. $75.00 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786376
Principal investigator 1 ModernaTX, Inc. $75.00 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1039786383
Principal investigator 1 PFIZER INC. $7,219.24 05/26/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045864661
Principal investigator 1 Janssen Research & Development, LLC $536.00 05/25/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120171
Principal investigator 1 Roche Diagnostics Operations, Inc. $8,651.16 05/25/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051509383
Principal investigator 1 Janssen Pharmaceuticals, Inc $12,870.00 05/24/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094763
Principal investigator 1 ModernaTX, Inc. $2,500.00 05/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040202611
Principal investigator 1 ModernaTX, Inc. $62,417.60 05/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040211043
Principal investigator 1 PFIZER INC. $1,356.80 05/18/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045982621
Principal investigator 1 ModernaTX, Inc. $23,757.60 05/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Observational secondary-use comparative effectiveness cohort study with tokenized clinical trial and real-world data. No dispute reported 06/30/2026 1040211885
Principal investigator 1 Janssen Pharmaceuticals, Inc $4,410.00 05/12/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094761
Principal investigator 1 PFIZER INC. $678.40 05/10/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046190291
Principal investigator 1 ModernaTX, Inc. $16,986.71 05/05/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040209667
Principal investigator 1 ModernaTX, Inc. $2,885.02 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609297
Principal investigator 1 ModernaTX, Inc. $2,885.02 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609391
Principal investigator 1 ModernaTX, Inc. $18.23 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609407
Principal investigator 1 ModernaTX, Inc. $2,703.03 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609421
Principal investigator 1 ModernaTX, Inc. $2,885.02 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609501
Principal investigator 1 ModernaTX, Inc. $2,703.03 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609517
Principal investigator 1 ModernaTX, Inc. $2,885.02 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609611
Principal investigator 1 ModernaTX, Inc. $18.23 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609727
Principal investigator 1 ModernaTX, Inc. $18.23 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609795
Principal investigator 1 ModernaTX, Inc. $18.23 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609811
Principal investigator 1 ModernaTX, Inc. $18.23 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609827
Principal investigator 1 ModernaTX, Inc. $2,885.02 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609839
Principal investigator 1 ModernaTX, Inc. $18.23 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609917
Principal investigator 1 ModernaTX, Inc. $2,703.03 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609931
Principal investigator 1 ModernaTX, Inc. $2,703.03 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609947
Principal investigator 1 ModernaTX, Inc. $2,885.02 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609963
Principal investigator 1 ModernaTX, Inc. $2,885.02 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609979
Principal investigator 1 ModernaTX, Inc. $2,703.03 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040609995
Principal investigator 1 ModernaTX, Inc. $2,885.02 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040610009
Principal investigator 1 ModernaTX, Inc. $18.23 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040610025
Principal investigator 1 ModernaTX, Inc. $18.23 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040610043
Principal investigator 1 ModernaTX, Inc. $2,703.03 05/05/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040610065
Principal investigator 1 ModernaTX, Inc. $41,024.40 05/03/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040210419
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040532573
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040532589
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040532605
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040532625
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040532643
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040532657
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040532673
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040532689
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040532705
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040532721
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040532737
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040532755
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537561
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537577
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537593
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537611
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537625
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537643
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537659
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537675
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537691
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537707
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537723
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537739
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537755
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537771
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040537787
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542379
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542397
Principal investigator 1 ModernaTX, Inc. $164.04 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542413
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542429
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542443
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542459
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542473
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542489
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542505
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542527
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542543
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542561
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542577
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040542593
Principal investigator 1 ModernaTX, Inc. $2,443.98 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547565
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547581
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547597
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547615
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547631
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547647
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547663
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547679
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547695
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547713
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547729
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547745
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547763
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547779
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040547795
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552427
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552443
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552459
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552475
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552492
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552509
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552525
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552541
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040552559
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557097
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557115
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557131
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557147
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557163
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557175
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557194
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557211
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557225
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557241
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557257
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557273
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557289
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557305
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557321
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557337
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040557353
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562357
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562373
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562389
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562405
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562425
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562441
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562457
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040562473
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567347
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567363
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567379
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567395
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567411
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567427
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567443
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567459
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567475
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567491
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567509
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567525
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040567541
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572795
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572811
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572829
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572845
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572861
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572877
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572893
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572909
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572925
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572941
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572957
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572973
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040572989
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040573007
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040573023
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040573038
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578163
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578179
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578195
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578211
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578225
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578241
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578257
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578273
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578287
Principal investigator 1 ModernaTX, Inc. $726.57 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578303
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578321
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578347
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040578363
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583339
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583355
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583369
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583385
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583399
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583415
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583431
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583449
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040583467
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588633
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588649
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588667
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588681
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588697
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588717
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588731
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588749
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588763
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588781
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588797
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588813
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588829
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588845
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588861
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040588877
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040593917
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040593935
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040593951
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040593969
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040593985
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594001
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594017
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594031
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594047
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594063
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040594081
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598639
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598653
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598669
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598685
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598701
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598717
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598733
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598749
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598765
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598781
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598797
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598811
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598829
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598845
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040598859
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040603683
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040603701
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040603715
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040603731
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040603747
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040603763
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040603779
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040603795
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040603811
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040603827
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040603843
Principal investigator 1 ModernaTX, Inc. $1,172.47 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040603859
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608443
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608459
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608475
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608491
Principal investigator 1 ModernaTX, Inc. $12.15 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608507
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608523
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608539
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608555
Principal investigator 1 ModernaTX, Inc. $538.25 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608571
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608587
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608601
Principal investigator 1 ModernaTX, Inc. $659.75 05/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040608617
Principal investigator 1 Roche Diagnostics Operations, Inc. $13,457.36 04/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051508529
Principal investigator 1 ModernaTX, Inc. $166.50 04/20/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - CINCINNATI
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042141887
Principal investigator 1 ModernaTX, Inc. $95,647.20 04/19/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040210353
Principal investigator 1 ModernaTX, Inc. $745.19 04/14/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040528685
Principal investigator 1 ModernaTX, Inc. $6,750.00 04/05/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040202473
Principal investigator 1 ModernaTX, Inc. $10,935.00 04/05/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040202487
Principal investigator 1 ModernaTX, Inc. $65,700.00 04/05/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040202499
Principal investigator 1 ModernaTX, Inc. $45,105.29 04/03/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040208587
Principal investigator 1 ModernaTX, Inc. $6,750.00 03/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040202435
Principal investigator 1 ModernaTX, Inc. $6,750.00 03/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040202449
Principal investigator 1 ModernaTX, Inc. $45,850.00 03/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040202387
Principal investigator 1 ModernaTX, Inc. $6,750.00 03/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040202399
Principal investigator 1 ModernaTX, Inc. $6,750.00 03/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040202411
Principal investigator 1 ModernaTX, Inc. $6,750.00 03/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040202423
Principal investigator 1 ModernaTX, Inc. $35,640.40 03/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040209205
Principal investigator 1 Janssen Pharmaceuticals, Inc $18,508.00 03/22/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094673
Principal investigator 1 Janssen Research & Development, LLC $6,092.00 03/20/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120047
Principal investigator 1 Janssen Research & Development, LLC $450.00 03/17/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120023
Principal investigator 1 ModernaTX, Inc. $37,795.95 03/15/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040208931
Principal investigator 1 ModernaTX, Inc. $16,337.70 03/15/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1040208941
Principal investigator 1 ModernaTX, Inc. $39,912.00 03/15/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040209179
Principal investigator 1 ModernaTX, Inc. $166.50 03/15/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - CINCINNATI
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042141879
Principal investigator 1 Roche Diagnostics Operations, Inc. $1,922.48 03/13/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051506209
Principal investigator 1 Roche Diagnostics Operations, Inc. $615.68 03/13/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051506489
Principal investigator 1 ModernaTX, Inc. $53,703.26 03/03/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040208543
Principal investigator 1 ModernaTX, Inc. $40,868.00 03/01/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 1040209155
Principal investigator 1 Janssen Pharmaceuticals, Inc $16,302.00 02/23/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094669
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $6,718.50 02/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH CINCINNATI
A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin No dispute reported 06/30/2026 1006162261
Principal investigator 1 Horizon Therapeutics plc $23,042.23 02/22/2023 Non-covered Recipient Entity
D&H TAMARAC RESEARCH CENTER
INFUSION DURATION STUDY TO ASSESS TOLERABILITY OF PEGLOTICASE ADMINISTERED WITH A SHORTER INFUSION DURATION IN SUBJECTS WITH UNCONTROLLED GOUT RECEIVING METHOTREXATE No dispute reported 06/30/2026 986927853
Principal investigator 1 Roche Diagnostics Operations, Inc. $4,806.20 02/20/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051505675
Principal investigator 1 Janssen Research & Development, LLC $23,400.00 02/15/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120027
Principal investigator 1 PFIZER INC. $2,250.00 02/15/2023 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045863313
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,700.00 02/09/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-blind, Parallel-group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) & Licogliflozin (LIK066) Combination Therapy, Compared to Each Monotherapy, for Treatment of Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis No dispute reported 06/30/2026 1017240905
Principal investigator 1 Janssen Research & Development, LLC $6,360.00 02/08/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120031
Principal investigator 1 Roche Diagnostics Operations, Inc. $3,270.80 01/30/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051505909
Principal investigator 1 Roche Diagnostics Operations, Inc. $9,612.40 01/26/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
CIMRD005476 No dispute reported 06/30/2026 1051505257
Principal investigator 1 Janssen Pharmaceuticals, Inc $19,871.00 01/25/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094675
Principal investigator 1 Janssen Research & Development, LLC $41,409.00 01/25/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120035
Principal investigator 1 Janssen Pharmaceuticals, Inc $30,481.00 01/13/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094677
Principal investigator 1 Janssen Research & Development, LLC $207,890.00 01/13/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120039
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406519
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406535
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406551
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406565
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406609
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406625
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406642
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406657
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406675
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406689
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406705
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406721
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406737
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040406751
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410323
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410337
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410355
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410369
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410381
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410400
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410417
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410429
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410441
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410455
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040410473
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413743
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413759
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413773
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413789
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413805
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413817
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413833
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413849
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413863
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413879
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413895
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413907
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413925
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413941
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040413957
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417233
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417247
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417261
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417279
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417295
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417311
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417327
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417341
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417357
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417371
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417387
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417403
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417421
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417435
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417450
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040417467
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420517
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420529
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420541
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420553
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420564
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420577
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420591
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420603
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420615
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420627
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420637
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420649
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420663
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040420675
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423563
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423575
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423587
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423599
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423609
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423625
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423639
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423649
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423663
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423675
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423687
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423699
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423711
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423725
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423741
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423753
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040423765
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426555
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426569
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426581
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426593
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426607
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426619
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426631
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426643
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426655
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426669
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426681
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426691
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426705
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426717
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426729
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426741
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426753
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426765
Principal investigator 1 ModernaTX, Inc. $2,443.98 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426777
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040426789
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429431
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429443
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429455
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429467
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429479
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429491
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429505
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429517
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429529
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429541
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429553
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429567
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429579
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429591
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429603
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429615
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429627
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429639
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040429651
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432234
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432243
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432255
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432267
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432279
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432291
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432303
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432315
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432329
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432341
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432353
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432365
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432379
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432389
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432399
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432411
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432423
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432433
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432445
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040432457
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040434889
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040434901
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040434913
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040434927
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040434939
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040434951
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040434963
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040434975
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040434987
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040434999
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435011
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435023
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435035
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435047
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435059
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435071
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435083
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435095
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435107
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435119
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435131
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435145
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435157
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435169
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435183
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435197
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435207
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435221
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435233
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040435245
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438073
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438085
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438101
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438113
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438125
Principal investigator 1 ModernaTX, Inc. $2,443.98 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438137
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438149
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438161
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438175
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438187
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438201
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438213
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438227
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438239
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438251
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438263
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040438275
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440779
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440791
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440803
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440815
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440827
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440837
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440849
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440861
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440873
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440883
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440895
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440909
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440921
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440933
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440945
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440959
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440971
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440985
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040440997
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441009
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441021
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441033
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441045
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441057
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441069
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441081
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040441093
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040443918
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040443933
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040443945
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040443957
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040443969
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040443981
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040443993
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444003
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444015
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444029
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444041
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444051
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444063
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444075
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444087
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444099
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444111
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444123
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444135
Principal investigator 1 ModernaTX, Inc. $2,443.98 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444147
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444161
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444171
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040444185
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040447947
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040447964
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040447981
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040447997
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448011
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448027
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448043
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448059
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448079
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448095
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448109
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448125
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448143
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448157
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040448173
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451569
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451585
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451601
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451617
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451631
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451648
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451667
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451683
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451699
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451713
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451725
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451745
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451759
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451771
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451787
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040451801
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455237
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455253
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455267
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455285
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455299
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455313
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455333
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455347
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455365
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455381
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455401
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455417
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455433
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455453
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455467
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040455483
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459156
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459171
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459187
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459203
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459219
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459233
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459249
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459265
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459285
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459303
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459319
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459335
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459351
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459365
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459383
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459397
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459413
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459429
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459447
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459463
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459481
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459494
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459511
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040459529
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463243
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463263
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463279
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463295
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463311
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463327
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463341
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463357
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463373
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463389
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463405
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463423
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463437
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463453
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463469
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463485
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463501
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463517
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463533
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463549
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463565
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040463581
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040466933
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040466949
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040466963
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040466981
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040466999
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467015
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467029
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467045
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467063
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467077
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467093
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467109
Principal investigator 1 ModernaTX, Inc. $2,032.69 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467125
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467141
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467159
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467176
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467191
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467207
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467221
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467239
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467257
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467273
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467291
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040467307
Principal investigator 1 ModernaTX, Inc. $2,032.69 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471025
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471041
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471057
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471073
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471089
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471105
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471123
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471143
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471160
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471175
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471195
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471215
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471231
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471247
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471263
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471282
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471299
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471315
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471328
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471343
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471359
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471375
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040471393
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475153
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475167
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475185
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475201
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475215
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475231
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475247
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475263
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475279
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475295
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475311
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475325
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475341
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475357
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475375
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475391
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475407
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475423
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475439
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475453
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475469
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475485
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475501
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475517
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475531
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475547
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475563
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040475579
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479033
Principal investigator 1 ModernaTX, Inc. $1,172.47 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479049
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479065
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479081
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479097
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479115
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479131
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479147
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479163
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479179
Principal investigator 1 ModernaTX, Inc. $2,443.98 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479191
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479209
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479225
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479241
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479257
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479273
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479289
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479305
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479321
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479337
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479351
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040479367
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483127
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483143
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483159
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483176
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483193
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483209
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483225
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483241
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483259
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483275
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483291
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483307
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483325
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483341
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483357
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483375
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483391
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483407
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483423
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483439
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483455
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483471
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483493
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483509
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483525
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040483541
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486763
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486779
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486795
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486811
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486827
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486841
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486861
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486877
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486893
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486911
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486927
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486943
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040486959
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490381
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490397
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490411
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490429
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490443
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490461
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490475
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490493
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490511
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490529
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490545
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490561
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490577
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490593
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490609
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490625
Principal investigator 1 ModernaTX, Inc. $1,172.47 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490641
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490657
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490673
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490689
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490705
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490721
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490737
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040490753
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040493907
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040493923
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040493939
Principal investigator 1 ModernaTX, Inc. $2,443.98 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040493957
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040493975
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040493991
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494005
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494021
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494039
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494055
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494071
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494087
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494103
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494117
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494131
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494151
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494167
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494181
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494197
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494213
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040494235
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040497835
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040497851
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040497869
Principal investigator 1 ModernaTX, Inc. $1,172.47 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040497885
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040497903
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040497919
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040497935
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040497951
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040497967
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040497985
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498003
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498019
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498035
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498051
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498071
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498083
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498099
Principal investigator 1 ModernaTX, Inc. $1,172.47 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498115
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498135
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498151
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040498167
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501529
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501545
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501563
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501581
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501599
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501615
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501631
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501645
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501661
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501679
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501695
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501711
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501727
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501743
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501759
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501775
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040501791
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505285
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505301
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505317
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505339
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505355
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505369
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505387
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505403
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505419
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505435
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505451
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505467
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505483
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505501
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505517
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505531
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505547
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505573
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505589
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505605
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040505621
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509283
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509299
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509315
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509329
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509345
Principal investigator 1 ModernaTX, Inc. $1,172.47 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509361
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509383
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509397
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509415
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509428
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509445
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509455
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509473
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509491
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509503
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040509517
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512765
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512781
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512795
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512811
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512829
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512845
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512861
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512877
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512889
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512909
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512923
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512939
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512955
Principal investigator 1 ModernaTX, Inc. $2,032.69 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512973
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040512987
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513003
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513019
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513035
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513055
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513067
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513085
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513099
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513113
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513131
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513147
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513163
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513179
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040513195
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517167
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517183
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517199
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517215
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517233
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517245
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517261
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517279
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517295
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517315
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517331
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517347
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517365
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517379
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517395
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517413
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517429
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517447
Principal investigator 1 ModernaTX, Inc. $659.75 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517463
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517479
Principal investigator 1 ModernaTX, Inc. $538.25 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517493
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517509
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517525
Principal investigator 1 ModernaTX, Inc. $12.15 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517541
Principal investigator 1 ModernaTX, Inc. $3,644.40 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517557
Principal investigator 1 ModernaTX, Inc. $726.57 01/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1040517573
Principal investigator 1 Janssen Pharmaceuticals, Inc $3,570.00 01/06/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094679
Principal investigator 1 Janssen Research & Development, LLC $295,560.00 01/06/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120043
Principal investigator 1 Janssen Research & Development, LLC $49,135.00 01/04/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 986120051